Referred to the House Committee on Energy and Commerce.
The bill amends the Federal Food, Drug, and Cosmetic Act to add new reporting and transparency requirements for medical device manufacturers. Manufacturers must notify FDA before making device design or reprocessing instruction changes, and must notify FDA within five days after widely disseminated communications to foreign health care providers about design, reprocessing, or safety concerns.
Liberal emphasizes patient-safety transparency; conservatives emphasize regulatory burden.
Relative to its intended legislative type, this bill constitutes a substantive amendment to the Federal Food, Drug, and Cosmetic Act that clearly creates new obligations and enforcement consequences and assigns regulatory responsibilities to the Secretary.
The bill amends the Federal Food, Drug, and Cosmetic Act to add new reporting and transparency requirements for medical device manufacturers.
Manufacturers must notify FDA before making device design or reprocessing instruction changes, and must notify FDA within five days after widely disseminated communications to foreign health care providers about design, reprocessing, or safety concerns.
The bill adds rapid assessment tests for reusable-device reprocessing to the device definition and directs FDA to list types of such tests that require validated instructions and validation data as part of premarket notifications.
A modest, safety-oriented regulatory tightening with limited fiscal impact; plausible passage but slowed by procedural hurdles and stakeholder pushback.
Relative to its intended legislative type, this bill constitutes a substantive amendment to the Federal Food, Drug, and Cosmetic Act that clearly creates new obligations and enforcement consequences and assigns regulatory responsibilities to the Secretary. The statutory changes are specific in key respects (reporting triggers, definitions, deadlines) but leave several implementation, resourcing, and exception issues unaddressed.
Liberal emphasizes patient-safety transparency; conservatives emphasize regulatory burden.
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberal emphasizes patient-safety transparency; conservatives emphasize regulatory burden.
Likely supportive because the bill increases transparency, strengthens reprocessing safety, and holds manufacturers accountable.
It aligns with priorities on patient safety and preventing device-related infections.
They may want stronger enforcement resources and protections for equitable access to necessary tests.
Generally favorable as an incremental safety and transparency measure if implemented pragmatically.
Support hinges on minimizing needless administrative delay and keeping compliance burdens proportionate to risk.
Will look for clear definitions, timelines, and FDA capacity assurances.
Skeptical of new pre-notification and rapid-reporting mandates due to added regulatory burden and potential harm to innovation.
Concerned that treating reporting failures as adulteration is punitive and could advantage larger firms.
Would favor narrowing scope and adding exemptions.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
A modest, safety-oriented regulatory tightening with limited fiscal impact; plausible passage but slowed by procedural hurdles and stakeholder pushback.
The bill has not accumulated any surfaced votes yet.
Liberal emphasizes patient-safety transparency; conservatives emphasize regulatory burden.
A modest, safety-oriented regulatory tightening with limited fiscal impact; plausible passage but slowed by procedural hurdles and stakehol…
Relative to its intended legislative type, this bill constitutes a substantive amendment to the Federal Food, Drug, and Cosmetic Act that clearly creates new obligations and enforcement consequences and assigns regulato…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.